{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-058688","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2023-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.857893+00:00","generated_at":"2026-06-07T09:51:49.939995+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Roivant reports positive Phase 2 batoclimab data in Graves' disease; response >50%","bullets":["Initial cohort in Phase 2 trial of batoclimab in Graves' disease showed response rates meaningfully exceeding 50%.","Batoclimab 680 mg SC achieved up to 87% IgG reduction, mean 81% at 12 weeks; 340 mg showed lower reductions.","Across clinical parameters, numerically higher responses with 680 mg vs 340 mg, including ATD dose reduction and discontinuation.","Batoclimab generally well tolerated with no new safety signals observed in the initial data set.","Immunovant plans to focus future Graves' development on IMVT-1402, with details expected later in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-058688","json":"https://secwatch.observer/filing/0001140361-23-058688.json","markdown":"https://secwatch.observer/filing/0001140361-23-058688.md","text":"https://secwatch.observer/filing/0001140361-23-058688.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123058688/0001140361-23-058688-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123058688/ef20017126_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:51:49.939995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}